Abstract With acceleration of population aging and urbanization, the number of patients with cardiovascular diseases has gradually increased. Development of cardiovascular implantable devices have attracted increasing attentions in recent years. The high risk of thrombosis is a major factor limiting the application of cardiovascular implanted devices, that is why it is so important to construct anticoagulant coatings on the surface of cardiovascular implanted devices. In this review, we summarized the research progress of anticoagulant coating construction methods in both domestic and foreign researches, analyzed and discussed the conventional and latest anticoagulation strategies from the aspects of physical, chemical and biological methods. Existing problems and prospects of anticoagulation coating construction were also discussed.
Lei Shaojin,Zheng Yi,Shi Jie, et al. The Technologies and Perspectives of Anticoagulant Coating[J]. Chinese Journal of Biomedical Engineering, 2024, 43(3): 377-384.
[1] Bartoli-Leonard F, Aikawa E. Heart valve disease: challenges and new opportunities [J]. Front Cardiovasc Med, 2020,7:602271. [2] Radke D, Jia WenKai, Sharma D, et al. Tissue engineering at the blood-contacting surface: a review of challenges and strategies in vascular graft development [J]. Adv Healthc Mater, 2018,7(15): 1701461. [3] von Segesser LK, Weiss BM, Pasic M, et al. Risk and benefit of low systemic heparinization during open heart operations [J]. Ann Thorac Surg, 1994,58(2):391-397. [4] Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option [J]. Semin Dial, 2010,23(5):510-515. [5] Monroe D, Hoffman M, Roberts HR. Platelets and thrombin generation [J]. Arterioscl Throm Vas, 2002,22(9):1381-1389. [6] Wagner DD. New links between inflammation and thrombosis [J]. Arterioscl Throm Vas, 2005,25(7):1321-1324. [7] Polgar J, Matuskova J, Wagner DD. The p-selectin, tissue factor, coagulation triad [J]. J Thromb Haemost, 2005,3(8):1590-1596. [8] Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation [J]. Blood, 2005,106(5):1604-1611. [9] Andre P, Denis CV, Ware J, et al. Platelets adhere to and translocate on von willebrand factor presented by endothelium in stimulated veins [J]. Blood, 2000,96(10):3322-3328. [10] Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor v and its activation by factor Xa and thrombin [J]. J Biol Chem, 1990,265(28):17132-17140. [11] Rawala-Sheikh R, Ahmad SS, Monroe DM, et al. Role of gamma-carboxyglutamic acid residues in the binding of factor IXA to platelets and in factor-x activation [J]. Blood, 1992,79(2):398-405. [12] Xie Xi, Doloff JC, Yesilyurt V, et al. Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer [J]. Nat Biomed Eng, 2018,2(12):894-906. [13] Lee SeYeong, Lee Yunki, Thi PhuongLe, et al. Sulfobetaine methacrylate hydrogel-coated anti-fouling surfaces for implantable biomedical devices [J]. Biomaterials Research, 2018,22(1):3. [14] Yao Mengmeng, Wei Zhijian, Li Junjin, et al. Microgel reinforced zwitterionic hydrogel coating for blood-contacting biomedical devices [J]. Nat Commun, 2022,13(1):5339. [15] Hiob MA, She S, Muiznieks LD, et al. Biomaterials and modifications in the development of small-diameter vascular grafts [J]. Acs Biomater Sci Eng, 2017,3(5):712-723. [16] Laput OA, Vasenina IV, Shapovalova YG, et al. Low-temperature barrier discharge plasma modification of scaffolds based on polylactic acid [J]. ACS Appl Mater Inter, 2022,14(37):41742-41750. [17] Cassady AI, Hidzir NM, Grondahl L. Enhancing expanded poly(tetrafluoroethylene) (ePTFE) for biomaterials applications [J]. J Appl Polym Sci, 2014,131(15):40533. [18] Chandy T, Das GS, Wilson RF, et al. Use of plasma glow for surface-engineering biomolecules to enhance bloodcompatibility of dacron and PTFE vascular prosthesis [J]. Biomaterials, 2000,21(7):699-712. [19] De Mel A, Jell G, Stevens MM, et al. Biofunctionalization of biomaterials for accelerated in situ endothelialization: a review [J]. Biomacromolecules, 2008,9(11):2969-2979. [20] Li Peichuang, Cai Wanhao, Wang Kebing, et al. Selenium-functionalized polycarbonate-polyurethane for sustained in situ generation of therapeutic gas for blood-contacting materials [J]. Smart Materials in Medicine, 2022,3(361-373):361-373. [21] Ling Pinghua, Gao Xianping, Zang Xiaona, et al. Understanding the performance of metal-organic frameworks for modulation of nitric oxide release from s-nitrosothiols [J]. Chem Asian J, 2022,17(7): e202101358. [22] Zhang Xiangyun, Wang Yuanbo, Liu Jing, et al. A metal-organic-framework incorporated vascular graft for sustained nitric oxide generation and long-term vascular patency [J]. Cheml Eng J, 2021,421:129577. [23] Bubik S, Payer M, Arnetzl G, et al. Attachment and growth of human osteoblasts on different biomaterial surfaces [J]. Int J Comput Dent, 2017,20(3):229-243. [24] Sun Mingcong, Deng Jun, Tang Zengchao, et al. A correlation study of protein adsorption and cell behaviors on substrates with different densities of peg chains [J]. Colloid Surface B, 2014,122:134-142. [25] Wang Xueting, Deng Xudong, Zhang Tuodi, et al. A versatile hydrophilic and antifouling coating based on dopamine modified four-arm polyethylene glycol by one-step synthesis method [J]. ACS Macro Lett, 2022,11(6):805-812. [26] Matsubara T, Ziff M. Increased superoxide anion release from human-endothelial cells in response to cytokines [J]. J Immunol, 1986,137(10):3295-3298. [27] Chen Jiaxuan, Howell C, Haller CA, et al. An immobilized liquid interface prevents device associated bacterial infection in vivo [J]. Biomaterials, 2017,113: 80-92. [28] Leslie DC, Waterhouse A, Berthet JB, et al. A bioinspired omniphobic surface coating on medical devices prevents thrombosis and biofouling [J]. Nat Biotechnol 2014,32(11):1134-1140. [29] Zhang Pengchao, Lin Ling, Zang Dongmian, et al. Designing bioinspired anti-biofouling surfaces based on a superwettability strategy [J]. Small, 2017,13(4). 1503334. [30] Badv M, Imani SM, Weitz JI, et al. Lubricant-infused surfaces with built-in functional biomolecules exhibit simultaneous repellency and tunable cell adhesion [J]. Acs Nano, 2018,12(11):10890-10902. [31] Chuang YJ, Swanson R, Raja SM, et al. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin [J]. J Biol Chem, 2001,276(18):14961-14971. [32] Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin [J]. Mol Cell Biochem, 1982,48(3):161-182. [33] Ranucci M, Cirri S, Conti D, et al. Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction [J]. Ann Thorac Surg, 1996,61(1):76-81. [34] Korn RL, Fisher CA, Livingston ER, et al. The effects of carmeda bioactive surface on human blood components during simulated extracorporeal circulation [J]. J Thorac Cardiov Sur, 1996,111(5):1073-1084. [35] Johnell M, Elgue G, Larsson R, et al. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface [J]. J Thorac Cardiov Sur, 2002,124(2):321-332. [36] Xie De, Leng Yuxing, Jing Fenjie, et al. A brief review of bio-tribology in cardiovascular devices [J]. Biosurface and Biotribology, 2015,1(4):249-262. [37] Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition [J]. Brit J Haematol, 2012,159(5):528-540. [38] Meng Qinghe, Krahn J. Reverse pseudohyperkalemia in heparin plasma samples from a patient with chronic lymphocytic leukemia [J]. Clin Biochem, 2011,44(8):728-730. [39] Rajgopal R, Bear M, Butcher MK, et al. The effects of heparin and low molecular weight heparins on bone [J]. Thromb Res, 2008,122(3):293-298. [40] Yu Chenglong, Yang Huaguang, Wang Lu, et al. Surface modification of polytetrafluoroethylene (PTFE) with a heparin-immobilized extracellular matrix (ECM) coating for small-diameter vascular grafts applications [J]. Mat Sci Eng C, 2021,128: 112301. [41] Qiu Hua, Qi Pengkai, Liu Jingxia, et al. Biomimetic engineering endothelium-like coating on cardiovascular stent through heparin and nitric oxide-generating compound synergistic modification strategy [J]. Biomaterials, 2019,207:10-22. [42] Hansson KM, Nielsen S, Elg M, et al. The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood [J]. J Thromb Haemostasis, 2014,12(10):1678-1686. [43] Yau JW, Stafford AR, Liao P, et al. Mechanism of catheter thrombosis: Comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo [J]. Blood, 2011,118(25):6667-6674. [44] Chong GL, Reeck GR. Interaction of trypsin, β-factor XⅡa, and plasma kallikrein with a trypsin inhibitor isolated from barley seeds: A comparison with the corn inhibitor of activated hageman factor [J]. Thromb Res, 1987,48(2):211-221. [45] Yau JW, Stafford AR, Liao Peng, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo [J]. Acta Biomater, 2012,8(11):4092-4100. [46] Verhagen HJM, Heijnen-Snyder GJ, Thrombomodulin activity on mesothelial cells: Perspectives for mesothelial cells as an alternative for endothelial cells for cell seeding on vascular grafts [J]. Brit J Haematol, 1996,95(3):542-549. [47] Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition [J]. Arterioscl Throm Vas, 2005,25(7):1311-1320. [48] Qu Zheng, Krishnamurthy V, Haller CA, et al. Immobilization of actively thromboresistant assemblies on sterile blood-contacting surfaces [J]. Adv Healthc Mater, 2014,3(1):30-35. [49] Ham Hanmu, Qu Zi, Haller CA, et al. In situ regeneration of bioactive coatings enabled by an evolved staphylococcus aureus sortasea [J]. Nat Commun, 2016,7(1):11140. [50] Ham HO, Haller CA, Su Guowei, et al. A rechargeable anti-thrombotic coating for blood-contacting devices [J]. Biomaterials, 2021,276:121011. [51] Muller C, Haase M, Lemke S, et al. Hirudins and hirudin-like factors in hirudinidae: Implications for function and phylogenetic relationships [J]. Parasitol Res, 2017,116(1):313-325. [52] Zheng Zhiwen, Li Xueyang, Dai Xin, et al. Surface functionalization of anticoagulation and anti-nonspecific adsorption with recombinant hirudin modification [J]. Biomaterials Adv, 2022,135:212741. [53] Sun Qiqi, Si Jianghua, Zhao Lili, et al. Direct thrombin inhibitor-bivalirudin improved the hemocompatibility of electrospun polycaprolactone vascular grafts [J]. Compos Part B: Eng, 2022,234:109702. [54] Bellomo TR, Jeakle MA, Meyerhoff ME, et al. The effects of the combined argatroban/nitric oxide-releasing polymer on platelet microparticle-induced thrombogenicity in coated extracorporeal circuits [J]. Asaio J, 2021,67(5):573-582. [55] Pang Jonhon, Farhatnia Y, Godarzi F, et al. In situ endothelialization: Bioengineering considerations to translation [J]. Small, 2015,11(47):6248-6264. [56] Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors [J]. Nat Med, 2003,9(6):669-676. [57] Wang Hongguo, Yin Tai, Ge Seling, et al. Biofunctionalization of titanium surface with multilayer films modified by heparin-VEGF-fibronectin complex to improve endothelial cell proliferation and blood compatibility [J]. J Biomed Mater Res A, 2013,101(2):413-420. [58] Marinval N, Morenc M, Labour MN, et al. Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses [J]. Biomaterials, 2018,172:14-29. [59] Ye Xiaofeng, Wang Haozhe, Zhou Jingxin, et al. The effect of heparin-VEGF multilayer on the biocompatibility of decellularized aortic valve with platelet and endothelial progenitor cells [J]. PLoS ONE, 2013,8(1): e54622. [60] Lin Quankui, Ding Xin, Qiu Fuyu, et al. In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin-collagen multilayer [J]. Biomaterials, 2010,31(14):4017-4025. [61] Sun Anqi, Huang Xiuhong, Jiao Yanpeng, et al. Construction of biological factor-coated stent and its effect on promoting endothelialization [J]. Mat Sci Eng C, 2021,122:111943. [62] Bai Lingchuang, Zhao Jing, Li Qian, et al. Biofunctionalized electrospun pcl-pibmd/sf vascular grafts with peg and cell-adhesive peptides for endothelialization [J]. Macromol Biosci, 2019,19(2): e1800386. [63] Van de Locht A, Lamba D, Bauer M, et al. Two heads are better than one: Crystal structure of the insect derived double domain kazal inhibitor rhodniin in complex with thrombin [J]. The EMBO Journal, 1995,14(21):5149-5157.
